APA (7th ed.) Citation

McGrail, D., Pilié, P., Rashid, N., Voorwerk, L., Slagter, M., Kok, M., . . . Lin, S. (2022). Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. Annals of Oncology, 33(11), 1204. https://doi.org/10.1016/j.annonc.2022.07.009

Chicago Style (17th ed.) Citation

McGrail, D.J, et al. "Validation of Cancer-type-dependent Benefit from Immune Checkpoint Blockade in TMB-H Tumors Identified by the FoundationOne CDx Assay." Annals of Oncology 33, no. 11 (2022): 1204. https://doi.org/10.1016/j.annonc.2022.07.009.

MLA (9th ed.) Citation

McGrail, D.J, et al. "Validation of Cancer-type-dependent Benefit from Immune Checkpoint Blockade in TMB-H Tumors Identified by the FoundationOne CDx Assay." Annals of Oncology, vol. 33, no. 11, 2022, p. 1204, https://doi.org/10.1016/j.annonc.2022.07.009.